MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

Hepatoblastoma (HB) is the most common pediatric liver malignancy. High-risk patients have poor survival, and current chemotherapies are associated with significant toxicities. Targeted therapies are needed to improve outcomes and patient quality of life. Most HB cases are TP53 wild-type; therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodfield, Sarah E., Shi, Yan, Patel, Roma H., Chen, Zhenghu, Shah, Aayushi P., Srivastava, Rohit K., Whitlock, Richard S., Ibarra, Aryana M., Larson, Samuel R., Sarabia, Stephen F., Badachhape, Andrew, Starosolski, Zbigniew, Ghaghada, Ketan B., Sumazin, Pavel, Annis, D. Allen, López-Terrada, Dolores, Vasudevan, Sanjeev A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859402/
https://www.ncbi.nlm.nih.gov/pubmed/33536467
http://dx.doi.org/10.1038/s41598-021-82542-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859402/
https://www.ncbi.nlm.nih.gov/pubmed/33536467
http://dx.doi.org/10.1038/s41598-021-82542-4

Ejemplares similares